Advertisement
COYA vs VIR
Which Stock Would AI Choose? Coya Therapeutics (COYA) vs. Vir Biotechnology (VIR) Stock Comparison
Key Takeaways
- COYA is a clinical-stage biotechnology company focused on regulatory T cell (Treg) therapies for neurodegenerative diseases, while VIR spans infectious diseases and a growing oncology platform.
- COYA recently secured FDA Fast Track Designation for its lead ALS candidate and trades with a much smaller cash base and market capitalization than VIR.
- VIR closed an Astellas collaboration valued at up to $1.7 billion and holds a substantially larger cash position, supporting operations into 2028.
- Both companies are pre-profitability, carry clinical and regulatory risk, and remain driven primarily by pipeline catalysts rather than current revenue.
- For more details on these companies, explore COYA Major News and COYA Today's Price Move, as well as VIR Major News and VIR Today's Price Move.
- To see how AI evaluates stocks like these in real time, explore Trending AI Robots.
Introduction
This stock comparison examines COYA (Coya Therapeutics, Inc.) and VIR (Vir Biotechnology, Inc.), two development-stage biotechnology companies with different therapeutic focuses and very different financial profiles. Both stocks appeal to investors who follow clinical catalysts, regulatory milestones, and strategic partnerships, yet their risk-reward dynamics diverge meaningfully. Coya concentrates on Treg-based therapies for neurodegenerative conditions, while Vir operates across chronic hepatitis delta and an emerging oncology pipeline. Understanding their relative performance, market positioning, and catalysts can help traders and longer-term investors assess which profile better aligns with their objectives.
COYA Overview and Recent Performance
COYA is a Houston-based clinical-stage biotechnology company developing treatments designed to restore the anti-inflammatory function of regulatory T cells (Tregs). Its lead candidate, COYA 302, is being evaluated in the Phase 2 ALSTARS trial for amyotrophic lateral sclerosis (ALS), with a second indication in frontotemporal dementia (FTD) under development. In recent months, the company received FDA Fast Track Designation for COYA 302 in ALS, a status intended to expedite development and review of therapies for serious conditions.
Recent market activity has been shaped by incremental clinical progress, a licensing agreement with Dr. Reddy's Laboratories, and periodic capital raises. The company reported cash and cash equivalents of roughly $43 million as of mid-2026, a comparatively modest runway typical of early-stage biotechs. Analyst coverage skews strongly positive, with a consensus "Strong Buy" rating and price targets well above recent trading levels, reflecting optimism about the lead program rather than current financials. Sentiment has been influenced by trial enrollment updates, biomarker publications, and the expansion of the ALSTARS protocol.
VIR Overview and Recent Performance
VIR is a biotechnology company advancing treatments for chronic hepatitis delta and building an oncology franchise around its PRO-XTEN dual-masked T-cell engager (TCE) platform. Its hepatitis delta regimen of tobevibart plus elebsiran is progressing through the registrational ECLIPSE program, with top-line data anticipated in late 2026. In oncology, the company closed a global strategic collaboration with Astellas valued at up to $1.7 billion for VIR-5500, a PSMA-targeted TCE in prostate cancer.
Recent stock performance has been comparatively strong, with a meaningful year-to-date gain driven by partnership announcements and positive Phase 1 oncology data. The company ended its most recent quarter with roughly $809 million in cash, cash equivalents, and investments, and completed a $172.5 million follow-on offering, extending its expected runway into the second half of 2028. Despite this, VIR continues to report substantial net losses, reflecting high research and development spending across multiple programs.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's AI trading bots, each designed to trade thousands of different tickers using distinct strategies, timeframes, and risk parameters. With hundreds of AI Trading Bots available, Tickeron highlights only those currently best suited to prevailing market conditions, drawing on performance statistics, win rates, and consistency metrics to identify standout candidates. Because the bots vary in style, from short-term momentum approaches to longer-horizon trend strategies, investors can compare options that match their own time horizons and risk tolerance. Exploring the Trending AI Robots section offers a data-driven way to observe how automated systems are currently positioning across the market.
Head-to-Head Comparison
The clearest contrast between these two stocks is scale and financial positioning. VIR holds a substantially larger cash balance and a market capitalization several times that of COYA, giving it a longer runway and greater flexibility to absorb clinical setbacks. COYA, by contrast, operates with a leaner balance sheet and is more concentrated around a single lead asset, which raises both the concentration risk and the potential upside tied to that program's success.
In terms of growth drivers, VIR benefits from diversification across hepatitis delta and multiple oncology candidates, plus non-dilutive backing from partners such as Astellas. COYA is anchored to neurodegenerative disease, an area with high unmet need but long development timelines. On momentum, VIR has shown stronger recent share-price appreciation, while COYA trades at a lower price with analyst targets implying a wider perceived gap to fair value. Both carry binary clinical risk, though VIR's broader pipeline and deeper cash position may offer comparatively more resilience to any single readout.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance-sheet stability, catalyst diversity, and relative market positioning, Tickeron's AI would currently lean toward VIR. The company's stronger recent price momentum, larger cash reserves, and multiple near-term catalysts across two therapeutic areas present a steadier technical and fundamental profile than COYA's more concentrated, single-asset exposure. However, COYA's higher-risk, higher-reward setup could still appeal to investors with greater tolerance for volatility. The AI's assessment is probabilistic, reflecting current market data rather than a definitive forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COYA is a Hold and VIR is a Hold.
COYA in downward trend: 10-day moving average moved below 50-day moving average on October 14, 2026
The 10-day moving average for COYA crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
COYA moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for COYA moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for COYA entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where COYA's RSI Oscillator exited the oversold zone, 26 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 48 cases where COYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +18.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where COYA advanced for three days, in 168 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
COYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.621) is normal, around the industry mean (3.498). P/E Ratio (-2.794) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. COYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VIR in upward trend: 10-day moving average moved above 50-day moving average on October 30, 2026
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 69 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for VIR just turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 31 of 41 cases over the following month. The odds of a continued upward trend are 76%.
VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 130 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for VIR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 27 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 53 cases where VIR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.498). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VIR | ||
|---|---|---|
OUTLOOK RATING 1..100 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 96 | |
PRICE GROWTH RATING 1..100 | 35 | |
P/E GROWTH RATING 1..100 | 81 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| COYA | VIR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 81% |
| Momentum ODDS (%) | N/A | 1 day ago 77% |
| MACD ODDS (%) | N/A | 1 day ago 76% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 80% |
| Advances ODDS (%) | 3 days ago 86% | 3 days ago 76% |
| Declines ODDS (%) | 7 days ago 86% | 1 day ago 81% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 61% | 1 day ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COYA’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
- COYA’s FA Score: 1 green, 4 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COYA’s TA Score shows that 4 TA indicator(s) are bullish while VIR’s TA Score has 6 bullish TA indicator(s).
- COYA’s TA Score: 4 bullish, 5 bearish.
- VIR’s TA Score: 6 bullish, 4 bearish.
Price Growth
COYA (@Biotechnology) experienced а +1.61% price change this week, while VIR (@Biotechnology) price change was +17.20% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
COYA is expected to report earnings on Nov 11, 2026.
VIR is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
COYA and
Correlation & Price change
A.I.dvisor indicates that over the last year, COYA has been loosely correlated with EDIT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if COYA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To COYA | 1D Price Change % | ||
|---|---|---|---|---|
| COYA | 100% | +1.58% | ||
| EDIT - COYA | 51% Loosely correlated | -4.99% | ||
| VIR - COYA | 48% Loosely correlated | -0.15% | ||
| INMB - COYA | 44% Loosely correlated | N/A | ||
| CADL - COYA | 44% Loosely correlated | -1.39% | ||
| RXRX - COYA | 44% Loosely correlated | +1.13% | ||
More | ||||
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | -0.15% | ||
| BEAM - VIR | 54% Loosely correlated | +2.62% | ||
| EDIT - VIR | 54% Loosely correlated | -4.99% | ||
| SLDB - VIR | 53% Loosely correlated | +6.00% | ||
| BNTC - VIR | 52% Loosely correlated | +2.05% | ||
| DNLI - VIR | 52% Loosely correlated | -0.60% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CHAU | 17.08 | 0.25 | +1.46% |
| Direxion Daily CSI 300 China A Share Bull 2X ETF (CHAU) | |||
| WTMF | 39.14 | 0.19 | +0.50% |
| WisdomTree Managed Futures Strategy Fund (WTMF) | |||
| FDV | 34.39 | 0.07 | +0.20% |
| Federated Hermes U.S. Strategic Dividend ETF (FDV) | |||
| RNEM | 57.08 | -0.01 | -0.02% |
| First Trust Emerging Markets Equity Select ETF (RNEM) | |||
| GJS | 23.01 | -0.11 | -0.48% |
| Synthetic Fixed-Income Securities STRATS 2006-2 Goldman Sachs Group | |||